[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase 3positivedivarasibPositive
AI Analysis
Summary
Roche announced that its KRAS G12C inhibitor divarasib demonstrated superiority in a head-to-head Phase III trial against approved competitors in non-small cell lung cancer patients.
Clinical Trial Data
Phase
III
Primary Endpoint
Met
Outcome Details
divarasib showed superiority in head-to-head phase III trial against approved KRAS G12C inhibitors
Importance:8/10
Sentiment:
0.85
KRASG12C inhibitornon-small cell lung cancerhead-to-head comparisonPhase 3 data
Related Companies
Read the original article
Published by yahoo_finance on July 2, 2026 5:00 AM